Holen Sie sich die Stockscreener-App
9.90
7.03%
0.65
Vorhandelsmarkt:
9.89
-0.010
-0.10%
Schlusskurs vom Vortag:
$9.25
Offen:
$9.45
24-Stunden-Volumen:
2.05M
Relative Volume:
2.80
Marktkapitalisierung:
$539.95M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+6.80%
1M Leistung:
-31.72%
6M Leistung:
-50.52%
1J Leistung:
+0.00%
1-Tages-Spanne:
$9.303
$10.32
1-Wochen-Bereich:
$8.94
$10.32
52-Wochen-Spanne:
$7.80
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Firmenname
Bicara Therapeutics Inc
Sektor
Branche
Telefon
617-785-8308
Adresse
245 MAIN STREET, CAMBRIDGE
Vergleichen Sie BCAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
9.90 | 544.27M | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-23 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | Eingeleitet | Wells Fargo | Underweight |
| 2025-02-06 | Eingeleitet | Wedbush | Outperform |
| 2024-12-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-05 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-10-08 | Eingeleitet | Stifel | Buy |
| 2024-10-08 | Eingeleitet | TD Cowen | Buy |
Alle ansehen
Bicara Therapeutics Inc Aktie (BCAX) Neueste Nachrichten
Stifel reiterates Buy rating on Bicara Therapeutics stock - Investing.com Australia
Cantor Fitzgerald reiterates overweight rating on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Bicara Therapeutics stock By Investing.com - Investing.com India
Bicara Responds to Rival Merus With Early Survival Data at #ASCO25 - BioSpace
Cantor Fitzgerald reiterates overweight rating on Bicara Therapeutics stock - Investing.com
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara presents promising early-stage data in head and neck cancers - The Business Journals
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus ... - Enidnews.com
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 - GlobeNewswire
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 - GlobeNewswire Inc.
Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients - MSN
Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update - Insider Monkey
Bicara Therapeutics Inc. (NASDAQ:BCAX) Shares Bought by Millennium Management LLC - Defense World
PIZZA PIZZA ROYALTY CORP. ANNOUNCES MAY DIVIDEND and TIMING OF ANNUAL GENERAL MEETING - The Globe and Mail
159,043 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Purchased by Northern Trust Corp - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Earns “Outperform” Rating from Wedbush - Defense World
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Raised to Equal Weight at Wells Fargo & Company - Defense World
Stifel maintains Bicara stock Buy rating, $48 target post-ASCO - Investing.com Australia
Stifel maintains Bicara stock Buy rating, $48 target post-ASCO By Investing.com - Investing.com Canada
112,476 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Acquired by Deutsche Bank AG - Defense World
Bicara falls after early-stage trial data for head and neck cancer therapy - MSN
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics - MSN
Bicara Therapeutics (NASDAQ:BCAX) Stock Rating Lowered by Wall Street Zen - Defense World
Wells Fargo Upgrades Bicara Therapeutics (BCAX) - Nasdaq
Bicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On? - Benzinga
Bicara: Stock Decline On FICERA Abstract Release Creates Buying Opportunity (NASDAQ:BCAX) - Seeking Alpha
Biotech Soars On 'Unprecedented' Results, Slamming Its Rival - Investor's Business Daily
Wells Fargo Upgrades Bicara Therapeutics to Equal Weight From Underweight, $8 Price Target - marketscreener.com
Bicara Therapeutics upgraded to Equal Weight from Underweight at Wells Fargo - TipRanks
Wells upgrades Bicara to Equal Weight with thesis played out - TipRanks
Gold Gains Over 1%; Ross Stores Shares Dip After Pulling Fiscal 2026 Outlook - Benzinga
Bicara stock falls after data for lead drug (BCAX:NASDAQ) - Seeking Alpha
Nasdaq Down Over 1%; Workday Shares Tumble After Q1 Results - Benzinga
Why Is Bicara Therapeutics Stock (BCAX) Down 30% Today? - TipRanks
Ross Stores, Deckers Outdoor, Xerox Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa in HPV-Negative HNSCC Drives Buy Rating - TipRanks
Promising Efficacy and Survival Data Drive Buy Rating for Bicara Therapeutics - TipRanks
Bicara Therapeutics to present head and neck cancer study data - Investing.com Australia
ASCO25 abstract roundup: Roche's Itovebi cuts risk of death; Merus' bispecific impresses in HNSCC, while Bicara's disappoints - FirstWord Pharma
Bicara Therapeutics publishes updated data from Phase 1/1b trial of Ficerafusp - TipRanks
Bicara Therapeutics to present head and neck cancer study data By Investing.com - Investing.com Nigeria
Bicara Therapeutics stock tumbles on clinical trial data - Investing.com Australia
Bicara Therapeutics stock tumbles on clinical trial data By Investing.com - Investing.com Nigeria
Bicara Therapeutics Inc. Announces Updated Interim Data from Phase 1/1b Trial of Ficerafusp Alfa in Head and Neck Cancer Ahead of ASCO Presentation - Nasdaq
Bicara Therapeutics Announces Publication of an Abstract - GlobeNewswire
Micro-Cap Tech Firm Reports Triple-Digit Revenue Growth as Shares Climb - The Globe and Mail
Research Analysts Set Expectations for BCAX FY2026 Earnings - Defense World
TD Cowen reiterates Buy on Bicara Therapeutics stock - Investing.com Australia
TD Cowen reiterates Buy on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria
FY2025 EPS Forecast for Bicara Therapeutics Cut by Analyst - Defense World
Finanzdaten der Bicara Therapeutics Inc-Aktie (BCAX)
Es liegen keine Finanzdaten für Bicara Therapeutics Inc (BCAX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
6.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):